Lactobacillus reuteri and use thereof

Patent metadata

Field	Value
Publication number	US-10968495-B2
Application number	US-201816109747-A
Country	US
Kind code	B2
Filing date	Aug 23, 2018
Priority date	Oct 17, 2017
Publication date	Apr 6, 2021
Grant date	Apr 6, 2021

Abstract

Provided is a strain CCFM8631 of Lactobacillus reuteri and use thereof. The strain CCFM8631 of Lactobacillus reuteri can significantly increase neurotransmitter 5-hydroxytryptamine level in peripheral blood, recover the hormone levels, for example testosterone and so on in peripheral blood of rat, normalize abnormal abundances of Blautia genus and Turicibacter genus, Oscillospira genus and Bifidobacterium genus in intestinal flora of rat affected by high-fat high-starch diet, show good tolerance to simulated gastrointestinal fluid and quickly colonize in intestinal, significantly improve pathological damages of tissues such as liver, duodenum and so on, and increase triglyceride and total cholesterol levels in serum and oral glucose tolerance of rat with metabolic syndrome caused by high-fat high-starch diet. The strain CCFM8631 of Lactobacillus reuteri can be used for preventing, relieving or treating metabolic disorder, such as metabolic syndrome, irritable bowel syndrome and mental diseases related to metabolic syndrome such as anxiety, depression and so on.

First claim

What is claimed is:

1. A method of improving metabolic syndrome, modulating intestinal flora, improving irritable bowel syndrome, modulating brain-gut axis, relieving anxiety and/or depression, comprising administering a strain CCFM8631 of Lactobacillus reuteri which is deposited at China General Microbiological Culture Collection Center (CGMCC) with an accession number CGMCC 14394, to a subject in need thereof.

2. The method according to claim 1 , wherein the improving of metabolic syndrome is to relieve the symptoms of hyperglycemia and hyperlipidemia, inflammation of liver and duodenum, and liver fibrosis; the modulating of intestinal flora is to normalize abnormal abundances of Blautia genus, Turicibacter genus, Oscillospira genus and Bifidobacterium genus in the intestinal flora; and the modulating of brain-gut axis and the relieving of anxiety and/or depression is to increase 5-hydroxytryptamine level in peripheral blood.

3. A method for preparing a composition, comprising: inoculating the strain CCFM8631 of Lactobacillus reuteri to MRS medium at an inoculum size of 2 to 4 wt %, culturing for 18 to 20 h at 37° C. under anaerobic condition, collecting bacteria, resuspending the bacteria with a protectant to a bacterial density of 10 10 CFU/mL, culturing the suspension at 37° C. for 50 to 70 minutes under anaerobic condition, and drying the resulting culture, wherein the strain CCFM8631 is deposited at China General Microbiological Culture Collection Center (CGMCC) with an accession number CGMCC 14394.

4. The method according to claim 3 , wherein the protectant is a aqueous solution containing 100 g/L to 150 g/L of nonfat milk powder, 100 g/L to 150 g/L of maltodextrin, and 140 g/L to 160 g/L of trehalose; the drying is vacuum freeze-drying after pre-freezing at −15 to −20° C. for 8 to 14 h.

Assignees

• Infinitos China Company Ltd
• Infinitus China Co Ltd

Inventors

• Ma Fangli
• Chen Wei
• Wang Gang
• Zhu Guangsu
• Wang Yuanyuan
• Xiao Lingyun
• Hu Minghua
• Zhang Hao
• Zhao Jianxin
• Ma Chung Wah

Classifications

• A23C11/106

  Addition of, or treatment with, microorganisms (A23C20/025 takes precedence) · CPC title

• A23L11/65

  Soy drinks · CPC title

• C12R2001/225

  Lactobacillus · CPC title

• C12N1/205 Primary

  Bacterial isolates · CPC title

• C12N1/20 Primary

  Bacteria; Culture media therefor · CPC title